China’s Shanghai Henlius Biotech says it will move forward with clinical trials for its HLX04-O proposed biosimilar version of Avastin (bevacizumab) for the treatment of wet age-related macular degeneration after its Investigational New Drug application was approved by the US Food and Drug Administration.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?